JP2014506253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506253A5 JP2014506253A5 JP2013547456A JP2013547456A JP2014506253A5 JP 2014506253 A5 JP2014506253 A5 JP 2014506253A5 JP 2013547456 A JP2013547456 A JP 2013547456A JP 2013547456 A JP2013547456 A JP 2013547456A JP 2014506253 A5 JP2014506253 A5 JP 2014506253A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- borono
- propyl
- hexanoic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000001424 substituent group Chemical group 0.000 claims description 78
- 125000001072 heteroaryl group Chemical group 0.000 claims description 77
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 75
- 150000001875 compounds Chemical class 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 48
- 229910052799 carbon Inorganic materials 0.000 claims description 46
- -1 alpha amino acid compound Chemical class 0.000 claims description 44
- 241000124008 Mammalia Species 0.000 claims description 39
- 210000002460 smooth muscle Anatomy 0.000 claims description 38
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- IFXZVZTUTKSTCF-UHFFFAOYSA-N 2-[3-(4-acetylpiperazin-1-yl)propyl]-2-amino-6-boronohexanoic acid Chemical compound CC(=O)N1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 IFXZVZTUTKSTCF-UHFFFAOYSA-N 0.000 claims description 14
- PJZAICPWHIIMRF-UHFFFAOYSA-N 2-amino-6-borono-2-(3-piperazin-1-ylpropyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCNCC1 PJZAICPWHIIMRF-UHFFFAOYSA-N 0.000 claims description 14
- KZLKEYDLEVVVGJ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3-methoxyphenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical group COC1=CC=CC(NC(=O)N2CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC2)=C1 KZLKEYDLEVVVGJ-UHFFFAOYSA-N 0.000 claims description 14
- 102000004452 Arginase Human genes 0.000 claims description 14
- 108700024123 Arginases Proteins 0.000 claims description 14
- AVPJLCOJTXEOAV-UHFFFAOYSA-N C1CN(CCCC(CCCC)C(O)=O)CCN1C(=O)C1=CC=C(C#N)C=C1 Chemical compound C1CN(CCCC(CCCC)C(O)=O)CCN1C(=O)C1=CC=C(C#N)C=C1 AVPJLCOJTXEOAV-UHFFFAOYSA-N 0.000 claims description 14
- WFBHRSAKANVBKH-UHFFFAOYSA-N N-hydroxyguanidine Chemical group NC(=N)NO WFBHRSAKANVBKH-UHFFFAOYSA-N 0.000 claims description 14
- 125000005620 boronic acid group Chemical group 0.000 claims description 14
- 230000002685 pulmonary effect Effects 0.000 claims description 14
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 210000005070 sphincter Anatomy 0.000 claims description 7
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 6
- 101001098814 Dictyostelium discoideum 3',5'-cyclic-nucleotide phosphodiesterase regA Proteins 0.000 claims description 6
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 claims description 6
- 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 6
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- UHJHOMWGKLNKSW-UHFFFAOYSA-N 2-amino-2-[3-[benzyl(ethyl)amino]propyl]-6-boronohexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(CC)CC1=CC=CC=C1 UHJHOMWGKLNKSW-UHFFFAOYSA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 4
- 239000002961 echo contrast media Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 210000005226 corpus cavernosum Anatomy 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- DMZDUZBVSGSJKK-ACGXKRRESA-N (2S)-2-amino-6-borono-2-[3-(1-carboxyethylamino)propyl]hexanoic acid Chemical compound OC(=O)C(C)NCCC[C@](N)(C(O)=O)CCCCB(O)O DMZDUZBVSGSJKK-ACGXKRRESA-N 0.000 claims description 2
- DKYMUJJLXCTWSM-CVRLYYSRSA-N (2s)-2-amino-6-borono-2-[3-[(1-carboxy-3-methylbutyl)amino]propyl]hexanoic acid Chemical compound CC(C)CC(C(O)=O)NCCC[C@](N)(C(O)=O)CCCCB(O)O DKYMUJJLXCTWSM-CVRLYYSRSA-N 0.000 claims description 2
- YHSUWYJIWKJAFG-VYIIXAMBSA-N (2s)-2-amino-6-borono-2-[3-[(1-methoxy-4-methyl-1-oxopentan-2-yl)amino]propyl]hexanoic acid Chemical compound COC(=O)C(CC(C)C)NCCC[C@](N)(C(O)=O)CCCCB(O)O YHSUWYJIWKJAFG-VYIIXAMBSA-N 0.000 claims description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 2
- OIOSDHQLKMVRQD-UHFFFAOYSA-N 2-[2-amino-2-[3-[4-(2-chlorophenyl)pyrazol-1-yl]piperidin-1-yl]propyl]-6-boronohexanoic acid Chemical compound C1N(C(N)(CC(CCCCB(O)O)C(O)=O)C)CCCC1N1N=CC(C=2C(=CC=CC=2)Cl)=C1 OIOSDHQLKMVRQD-UHFFFAOYSA-N 0.000 claims description 2
- CCFTXZXKNCVCRW-UHFFFAOYSA-N 2-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCC)C(O)=O)CCC1C1=CC=C(F)C=C1 CCFTXZXKNCVCRW-UHFFFAOYSA-N 0.000 claims description 2
- XJLITJHUQRBWPN-UHFFFAOYSA-N 2-acetamidoacetic acid;4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide Chemical compound CC(=O)NCC(O)=O.C1=CC(C(=N)N)=CC=C1NN=NC1=CC=C(C(N)=N)C=C1 XJLITJHUQRBWPN-UHFFFAOYSA-N 0.000 claims description 2
- JRPAMPYUINVTRE-UHFFFAOYSA-N 2-amino-2-(4-boronobutyl)-6-(3,4-dihydro-1h-isoquinolin-2-yl)hexanoic acid Chemical compound C1=CC=C2CN(CCCCC(CCCCB(O)O)(N)C(O)=O)CCC2=C1 JRPAMPYUINVTRE-UHFFFAOYSA-N 0.000 claims description 2
- KDWYCCPYIHPYCH-UHFFFAOYSA-N 2-amino-2-(4-boronobutyl)-6-[2-(4-fluorophenyl)piperidin-1-yl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCCN1CCCCC1C1=CC=C(F)C=C1 KDWYCCPYIHPYCH-UHFFFAOYSA-N 0.000 claims description 2
- JVXBSROYIBBRFJ-UHFFFAOYSA-N 2-amino-2-(4-boronobutyl)-6-[4-(3,4-dichlorophenyl)piperazin-1-yl]hexanoic acid Chemical compound C1CN(CCCCC(CCCCB(O)O)(N)C(O)=O)CCN1C1=CC=C(Cl)C(Cl)=C1 JVXBSROYIBBRFJ-UHFFFAOYSA-N 0.000 claims description 2
- XKKSNZAYJGFESW-UHFFFAOYSA-N 2-amino-2-(4-boronobutyl)-6-[4-[(3,4-difluorophenyl)methyl]piperidin-1-yl]hexanoic acid Chemical compound C1CN(CCCCC(CCCCB(O)O)(N)C(O)=O)CCC1CC1=CC=C(F)C(F)=C1 XKKSNZAYJGFESW-UHFFFAOYSA-N 0.000 claims description 2
- BPBSCILZHOHUHO-UHFFFAOYSA-N 2-amino-2-(4-boronobutyl)-6-piperazin-1-ylhexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCCN1CCNCC1 BPBSCILZHOHUHO-UHFFFAOYSA-N 0.000 claims description 2
- ISQZWVMUKBCATQ-UHFFFAOYSA-N 2-amino-2-[3-(2-benzylpiperidin-1-yl)propyl]-6-boronohexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCCC1CC1=CC=CC=C1 ISQZWVMUKBCATQ-UHFFFAOYSA-N 0.000 claims description 2
- ABRLPVPSSCYJFO-UHFFFAOYSA-N 2-amino-2-[3-(4-benzamidopiperidin-1-yl)propyl]-6-boronohexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1NC(=O)C1=CC=CC=C1 ABRLPVPSSCYJFO-UHFFFAOYSA-N 0.000 claims description 2
- BRWBTRDLVZIMIM-UHFFFAOYSA-N 2-amino-2-[3-(4-benzhydrylpiperazin-1-yl)propyl]-6-boronohexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BRWBTRDLVZIMIM-UHFFFAOYSA-N 0.000 claims description 2
- PRQHZEBQSNCYEO-UHFFFAOYSA-N 2-amino-2-[3-(4-benzylpiperazin-1-yl)propyl]-6-boronohexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=CC=C1 PRQHZEBQSNCYEO-UHFFFAOYSA-N 0.000 claims description 2
- SJSURLHRMWNOEB-UHFFFAOYSA-N 2-amino-2-[3-(azetidin-1-yl)propyl]-6-boronohexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCC1 SJSURLHRMWNOEB-UHFFFAOYSA-N 0.000 claims description 2
- GCUCLBYXPNHVCP-UHFFFAOYSA-N 2-amino-2-[3-(benzimidazol-1-yl)propyl]-6-boronohexanoic acid Chemical compound C1=CC=C2N(CCCC(CCCCB(O)O)(N)C(O)=O)C=NC2=C1 GCUCLBYXPNHVCP-UHFFFAOYSA-N 0.000 claims description 2
- SDISAHFEZPRFNC-UHFFFAOYSA-N 2-amino-2-[3-[3-(1,3-benzoxazol-2-yl)piperidin-1-yl]propyl]-6-boronohexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCCC1C1=NC2=CC=CC=C2O1 SDISAHFEZPRFNC-UHFFFAOYSA-N 0.000 claims description 2
- ZYPABFVXOIZNME-UCFFOFKASA-N 2-amino-2-[3-[4-[(2s)-2-amino-3-methylbutanoyl]oxypiperidin-1-yl]propyl]-6-boronohexanoic acid Chemical compound CC(C)[C@H](N)C(=O)OC1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 ZYPABFVXOIZNME-UCFFOFKASA-N 0.000 claims description 2
- WHORZLUFVHMYES-UHFFFAOYSA-N 2-amino-3-[3-(4-benzyl-4-decanoyloxypiperidin-1-yl)propyl]-6-boronohexanoic acid Chemical compound C=1C=CC=CC=1CC1(OC(=O)CCCCCCCCC)CCN(CCCC(CCCB(O)O)C(N)C(O)=O)CC1 WHORZLUFVHMYES-UHFFFAOYSA-N 0.000 claims description 2
- MHUBXSPFADMQDW-UHFFFAOYSA-N 2-amino-6-borono-2-(2-piperazin-1-ylethyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCN1CCNCC1 MHUBXSPFADMQDW-UHFFFAOYSA-N 0.000 claims description 2
- FPLQQVASXNNHMZ-UHFFFAOYSA-N 2-amino-6-borono-2-(2-piperidin-2-ylethyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCC1CCCCN1 FPLQQVASXNNHMZ-UHFFFAOYSA-N 0.000 claims description 2
- YZYDQVUTKBQKTJ-UHFFFAOYSA-N 2-amino-6-borono-2-(3-imidazol-1-ylpropyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1C=CN=C1 YZYDQVUTKBQKTJ-UHFFFAOYSA-N 0.000 claims description 2
- ORZSJZSNPWNMAZ-UHFFFAOYSA-N 2-amino-6-borono-2-(3-morpholin-4-ylpropyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCOCC1 ORZSJZSNPWNMAZ-UHFFFAOYSA-N 0.000 claims description 2
- ZXBYEQISFHBUQA-UHFFFAOYSA-N 2-amino-6-borono-2-(3-pyrrolidin-1-ylpropyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1 ZXBYEQISFHBUQA-UHFFFAOYSA-N 0.000 claims description 2
- RBVAUPSKVSBIOG-UHFFFAOYSA-N 2-amino-6-borono-2-(3-spiro[1h-2-benzofuran-3,4'-piperidine]-1'-ylpropyl)hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC21C1=CC=CC=C1CO2 RBVAUPSKVSBIOG-UHFFFAOYSA-N 0.000 claims description 2
- UZBXQNBMFCPICE-UHFFFAOYSA-N 2-amino-6-borono-2-(3-thiomorpholin-4-ylpropyl)hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCSCC1 UZBXQNBMFCPICE-UHFFFAOYSA-N 0.000 claims description 2
- KZHIKBONRPBXNG-UHFFFAOYSA-N 2-amino-6-borono-2-[2-[1-[(3,4-dichlorophenyl)methyl]piperidin-2-yl]ethyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCC1CCCCN1CC1=CC=C(Cl)C(Cl)=C1 KZHIKBONRPBXNG-UHFFFAOYSA-N 0.000 claims description 2
- WCYRKXCGRYIJRH-UHFFFAOYSA-N 2-amino-6-borono-2-[2-[1-[(3,4-dichlorophenyl)methyl]piperidin-3-yl]ethyl]hexanoic acid Chemical compound C1C(CCC(CCCCB(O)O)(N)C(O)=O)CCCN1CC1=CC=C(Cl)C(Cl)=C1 WCYRKXCGRYIJRH-UHFFFAOYSA-N 0.000 claims description 2
- YYJVYSBXZGKIJR-UHFFFAOYSA-N 2-amino-6-borono-2-[2-[1-[(3,4-difluorophenyl)methyl]piperidin-2-yl]ethyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCC1CCCCN1CC1=CC=C(F)C(F)=C1 YYJVYSBXZGKIJR-UHFFFAOYSA-N 0.000 claims description 2
- FLGMBTLQHHKAQB-UHFFFAOYSA-N 2-amino-6-borono-2-[2-[1-[(3,5-difluorophenyl)methyl]piperidin-2-yl]ethyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCC1CCCCN1CC1=CC(F)=CC(F)=C1 FLGMBTLQHHKAQB-UHFFFAOYSA-N 0.000 claims description 2
- GPYLVJBNODICFF-UHFFFAOYSA-N 2-amino-6-borono-2-[2-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]ethyl]hexanoic acid Chemical compound C1CN(CCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=C(Cl)C(Cl)=C1 GPYLVJBNODICFF-UHFFFAOYSA-N 0.000 claims description 2
- AULXBFOVMWZDJD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(1,3-thiazolidin-2-yl)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCC1NCCS1 AULXBFOVMWZDJD-UHFFFAOYSA-N 0.000 claims description 2
- FEWFZHXFKDOVJY-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(2-methoxyethylamino)propyl]hexanoic acid Chemical compound COCCNCCCC(N)(C(O)=O)CCCCB(O)O FEWFZHXFKDOVJY-UHFFFAOYSA-N 0.000 claims description 2
- HOLSSIRGZOSRNR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(2-phenylethylamino)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCNCCC1=CC=CC=C1 HOLSSIRGZOSRNR-UHFFFAOYSA-N 0.000 claims description 2
- CAIUNHCJFOTQGB-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(3,4-dihydro-1h-isoquinolin-2-yl)propyl]hexanoic acid Chemical compound C1=CC=C2CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC2=C1 CAIUNHCJFOTQGB-UHFFFAOYSA-N 0.000 claims description 2
- AUYUFTCGRPMQTR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(3-fluoro-4-phenylpiperidin-1-yl)propyl]hexanoic acid Chemical compound FC1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1C1=CC=CC=C1 AUYUFTCGRPMQTR-UHFFFAOYSA-N 0.000 claims description 2
- GMAMYAZILAOVSG-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(3-phenylazetidin-1-yl)propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CC1C1=CC=CC=C1 GMAMYAZILAOVSG-UHFFFAOYSA-N 0.000 claims description 2
- DCDSJOGIRPSVDK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(3-phenylpiperidin-1-yl)propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCCC1C1=CC=CC=C1 DCDSJOGIRPSVDK-UHFFFAOYSA-N 0.000 claims description 2
- FFJFBFSKGTUCRE-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(4-ethylpiperazin-1-yl)propyl]hexanoic acid Chemical compound CCN1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 FFJFBFSKGTUCRE-UHFFFAOYSA-N 0.000 claims description 2
- XNFZOEQJCMLVHJ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(4-hydroxypiperidin-1-yl)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCC(O)CC1 XNFZOEQJCMLVHJ-UHFFFAOYSA-N 0.000 claims description 2
- SWDAOXKFESLGRZ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(4-methyl-2-phenylpiperazin-1-yl)propyl]hexanoic acid Chemical compound C1N(C)CCN(CCCC(N)(CCCCB(O)O)C(O)=O)C1C1=CC=CC=C1 SWDAOXKFESLGRZ-UHFFFAOYSA-N 0.000 claims description 2
- MJDKZPARBWCXBG-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(4-methylpiperazin-1-yl)propyl]hexanoic acid Chemical compound CN1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 MJDKZPARBWCXBG-UHFFFAOYSA-N 0.000 claims description 2
- QJHUGBUKOMUTGT-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC21C(=O)NCN2C1=CC=CC=C1 QJHUGBUKOMUTGT-UHFFFAOYSA-N 0.000 claims description 2
- VVWYKAHJILQCLR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(5-phenyl-2,3-dihydropyrrol-1-yl)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCC=C1C1=CC=CC=C1 VVWYKAHJILQCLR-UHFFFAOYSA-N 0.000 claims description 2
- MSKGXUQDAKTGRQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(carboxymethylamino)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCNCC(O)=O MSKGXUQDAKTGRQ-UHFFFAOYSA-N 0.000 claims description 2
- AZDJHLHWFPOSQP-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(cyclohexylamino)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCNC1CCCCC1 AZDJHLHWFPOSQP-UHFFFAOYSA-N 0.000 claims description 2
- DLFDYLZMNZCLFD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(cyclopentylamino)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCNC1CCCC1 DLFDYLZMNZCLFD-UHFFFAOYSA-N 0.000 claims description 2
- PYHDFFKLEYOZTO-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(diethylamino)propyl]hexanoic acid Chemical compound CCN(CC)CCCC(N)(C(O)=O)CCCCB(O)O PYHDFFKLEYOZTO-UHFFFAOYSA-N 0.000 claims description 2
- LRFDXMRDOIVVCU-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(dimethylamino)propyl]hexanoic acid Chemical compound CN(C)CCCC(N)(C(O)=O)CCCCB(O)O LRFDXMRDOIVVCU-UHFFFAOYSA-N 0.000 claims description 2
- OEYNVEAFYMUOAR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-(oxan-4-ylamino)propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCNC1CCOCC1 OEYNVEAFYMUOAR-UHFFFAOYSA-N 0.000 claims description 2
- LFJOUDLRGZIUKY-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[(3,4-dichlorophenyl)methyl-ethylamino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(CC)CC1=CC=C(Cl)C(Cl)=C1 LFJOUDLRGZIUKY-UHFFFAOYSA-N 0.000 claims description 2
- INZPYLQFNQJBMV-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[(3,4-dichlorophenyl)methyl-methylamino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)CC1=CC=C(Cl)C(Cl)=C1 INZPYLQFNQJBMV-UHFFFAOYSA-N 0.000 claims description 2
- MEOYEIOPLSMTDI-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[(4-chlorophenyl)methyl-methylamino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)CC1=CC=C(Cl)C=C1 MEOYEIOPLSMTDI-UHFFFAOYSA-N 0.000 claims description 2
- IFYDEJJCNGCYSF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[(6-fluoro-3,4-dihydro-2h-chromen-4-yl)-methylamino]propyl]hexanoic acid Chemical compound C1=C(F)C=C2C(N(CCCC(N)(CCCCB(O)O)C(O)=O)C)CCOC2=C1 IFYDEJJCNGCYSF-UHFFFAOYSA-N 0.000 claims description 2
- MTCMVBUWPVKDSZ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[1-[(3,4-dichlorophenyl)methyl]piperidin-2-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCC1CCCCN1CC1=CC=C(Cl)C(Cl)=C1 MTCMVBUWPVKDSZ-UHFFFAOYSA-N 0.000 claims description 2
- IDJRCIWEFIJIHR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[1-[(3,4-difluorophenyl)methyl]piperidin-2-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCC1CCCCN1CC1=CC=C(F)C(F)=C1 IDJRCIWEFIJIHR-UHFFFAOYSA-N 0.000 claims description 2
- MKWUMTYROBOHDR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[1-[(3,5-difluorophenyl)methyl]piperidin-2-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCC1CCCCN1CC1=CC(F)=CC(F)=C1 MKWUMTYROBOHDR-UHFFFAOYSA-N 0.000 claims description 2
- ZEKCVJKKPZYOOU-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(3,4-dichlorophenyl)pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1C1=CC=C(Cl)C(Cl)=C1 ZEKCVJKKPZYOOU-UHFFFAOYSA-N 0.000 claims description 2
- GFCHLXOVZGYVGB-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(3-chlorophenyl)pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1C1=CC=CC(Cl)=C1 GFCHLXOVZGYVGB-UHFFFAOYSA-N 0.000 claims description 2
- JWAYXHCIVOIDNI-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(4-fluorophenyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCCC1C1=CC=C(F)C=C1 JWAYXHCIVOIDNI-UHFFFAOYSA-N 0.000 claims description 2
- UZILPCXOCFBHQK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(4-fluorophenyl)pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1C1=CC=C(F)C=C1 UZILPCXOCFBHQK-UHFFFAOYSA-N 0.000 claims description 2
- JYDVPEWROGQEBE-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(4-methoxyphenyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C1N(CCCC(N)(CCCCB(O)O)C(O)=O)CCCC1 JYDVPEWROGQEBE-UHFFFAOYSA-N 0.000 claims description 2
- UUXPMSWKNRWOPK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(4-phenylphenyl)pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1C1=CC=C(C=2C=CC=CC=2)C=C1 UUXPMSWKNRWOPK-UHFFFAOYSA-N 0.000 claims description 2
- WGTGEYVKUDPCCQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-(dimethylamino)ethylamino]propyl]hexanoic acid Chemical compound CN(C)CCNCCCC(N)(C(O)=O)CCCCB(O)O WGTGEYVKUDPCCQ-UHFFFAOYSA-N 0.000 claims description 2
- CRPVTBGKNPYYHN-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-[2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN1CCCC1C1=CC=CC=C1C(F)(F)F CRPVTBGKNPYYHN-UHFFFAOYSA-N 0.000 claims description 2
- XLTLALGVAZMDHD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[2-methoxyethyl(methyl)amino]propyl]hexanoic acid Chemical compound COCCN(C)CCCC(N)(C(O)=O)CCCCB(O)O XLTLALGVAZMDHD-UHFFFAOYSA-N 0.000 claims description 2
- APMRCUGZQYPOOP-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-(4-methylphenyl)azetidin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(C)=CC=C1C1CN(CCCC(N)(CCCCB(O)O)C(O)=O)C1 APMRCUGZQYPOOP-UHFFFAOYSA-N 0.000 claims description 2
- YGCBNGXXOOFXKA-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-(6-fluoro-1h-benzimidazol-2-yl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCCC1C1=NC2=CC(F)=CC=C2N1 YGCBNGXXOOFXKA-UHFFFAOYSA-N 0.000 claims description 2
- UCROHGDXNGWHAQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(3,4-dichlorophenyl)carbamoylamino]azetidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CC1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 UCROHGDXNGWHAQ-UHFFFAOYSA-N 0.000 claims description 2
- SUTNMRPGQWGGQE-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(3,4-dichlorophenyl)carbamoylamino]pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 SUTNMRPGQWGGQE-UHFFFAOYSA-N 0.000 claims description 2
- ZYRGOOGBIUAVHV-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(3,4-dichlorophenyl)sulfonylamino]pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1NS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 ZYRGOOGBIUAVHV-UHFFFAOYSA-N 0.000 claims description 2
- VWYJQOHBQIXVIR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(3-chloro-2-fluorobenzoyl)amino]azetidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CC1NC(=O)C1=CC=CC(Cl)=C1F VWYJQOHBQIXVIR-UHFFFAOYSA-N 0.000 claims description 2
- WIRSWJPYMXLDSM-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(4-fluorophenyl)carbamoylamino]azetidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CC1NC(=O)NC1=CC=C(F)C=C1 WIRSWJPYMXLDSM-UHFFFAOYSA-N 0.000 claims description 2
- HZJGOQKVEONWMK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[3-[(4-fluorophenyl)carbamoylamino]pyrrolidin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1NC(=O)NC1=CC=C(F)C=C1 HZJGOQKVEONWMK-UHFFFAOYSA-N 0.000 claims description 2
- YSCITUYCUAEITA-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(2-chlorobenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=CC=C1Cl YSCITUYCUAEITA-UHFFFAOYSA-N 0.000 claims description 2
- UQQOBXCQXGEWER-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(2-fluorobenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=CC=C1F UQQOBXCQXGEWER-UHFFFAOYSA-N 0.000 claims description 2
- PWGFFWMIORWKSQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(2-phenylethyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CCC1=CC=CC=C1 PWGFFWMIORWKSQ-UHFFFAOYSA-N 0.000 claims description 2
- MUAMXAUFRDMUTG-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(2-propan-2-ylphenoxy)piperidin-1-yl]propyl]hexanoic acid Chemical compound CC(C)C1=CC=CC=C1OC1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 MUAMXAUFRDMUTG-UHFFFAOYSA-N 0.000 claims description 2
- SQNCHQBEHGWKEN-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3,4-dichlorobenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=C(Cl)C(Cl)=C1 SQNCHQBEHGWKEN-UHFFFAOYSA-N 0.000 claims description 2
- DDIUEICEWFWJBS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3,4-dichlorophenyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C1=CC=C(Cl)C(Cl)=C1 DDIUEICEWFWJBS-UHFFFAOYSA-N 0.000 claims description 2
- VBTPNSJCKLAGGD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3,4-dichlorophenyl)sulfonylpiperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1S(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 VBTPNSJCKLAGGD-UHFFFAOYSA-N 0.000 claims description 2
- YZTGWYRRXXLLBT-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3-fluorobenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=CC(F)=C1 YZTGWYRRXXLLBT-UHFFFAOYSA-N 0.000 claims description 2
- PMFMVHVQBSHNAF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3-fluorophenyl)sulfonylpiperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1S(=O)(=O)C1=CC=CC(F)=C1 PMFMVHVQBSHNAF-UHFFFAOYSA-N 0.000 claims description 2
- FOSNGBYBVIAYRA-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(3-methoxybenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound COC1=CC=CC(C(=O)N2CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC2)=C1 FOSNGBYBVIAYRA-UHFFFAOYSA-N 0.000 claims description 2
- XCAGIBMRGQCWKW-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-carbamoylbenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(C(=O)N)=CC=C1C(=O)N1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 XCAGIBMRGQCWKW-UHFFFAOYSA-N 0.000 claims description 2
- NTVVGBGPLYAROW-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]propyl]hexanoic acid Chemical compound C1N(CCCC(CCCCB(O)O)(N)C(O)=O)CCC(C=2C=CC(Cl)=CC=2)=C1 NTVVGBGPLYAROW-UHFFFAOYSA-N 0.000 claims description 2
- WUQQQEORFARHNR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1(O)C1=CC=C(Cl)C=C1 WUQQQEORFARHNR-UHFFFAOYSA-N 0.000 claims description 2
- UBCCONYHOOGZQQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-fluorobenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=C(F)C=C1 UBCCONYHOOGZQQ-UHFFFAOYSA-N 0.000 claims description 2
- YGFGHWLWVNZPLQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1C(=O)C1=CC=C(F)C=C1 YGFGHWLWVNZPLQ-UHFFFAOYSA-N 0.000 claims description 2
- KRPONXHBNFCIHS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-fluorophenyl)sulfonylpiperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1S(=O)(=O)C1=CC=C(F)C=C1 KRPONXHBNFCIHS-UHFFFAOYSA-N 0.000 claims description 2
- XQRUDXUVJICSSK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-methoxybenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 XQRUDXUVJICSSK-UHFFFAOYSA-N 0.000 claims description 2
- REQBBTWLUWWMAO-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-methoxyphenyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 REQBBTWLUWWMAO-UHFFFAOYSA-N 0.000 claims description 2
- VVGTWLIVRXNHTF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-methylbenzoyl)piperazin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(C)=CC=C1C(=O)N1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 VVGTWLIVRXNHTF-UHFFFAOYSA-N 0.000 claims description 2
- VMAOBOJTPPEGHY-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 VMAOBOJTPPEGHY-UHFFFAOYSA-N 0.000 claims description 2
- OOMFHYWIVNSBRG-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1C1=NN=C(C=2C=CC=CC=2)O1 OOMFHYWIVNSBRG-UHFFFAOYSA-N 0.000 claims description 2
- RPGLWEHIDCWGRL-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-(pyrimidin-2-ylmethyl)piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1CC1=NC=CC=N1 RPGLWEHIDCWGRL-UHFFFAOYSA-N 0.000 claims description 2
- RSLXWSBZDJAGLK-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2,3-difluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=CC(F)=C1F RSLXWSBZDJAGLK-UHFFFAOYSA-N 0.000 claims description 2
- KZTHNMAWYTYXJV-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2,3-difluorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=CC(F)=C1F KZTHNMAWYTYXJV-UHFFFAOYSA-N 0.000 claims description 2
- NJRFMIHUOKIQTI-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2,4-difluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=C(F)C=C1F NJRFMIHUOKIQTI-UHFFFAOYSA-N 0.000 claims description 2
- PLOVUSDCMRIODX-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2,4-difluorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=C(F)C=C1F PLOVUSDCMRIODX-UHFFFAOYSA-N 0.000 claims description 2
- OHMLQHBHLWASBH-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2,5-difluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC(F)=CC=C1F OHMLQHBHLWASBH-UHFFFAOYSA-N 0.000 claims description 2
- VESCQETXRMCKLQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2-chlorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=CC=C1Cl VESCQETXRMCKLQ-UHFFFAOYSA-N 0.000 claims description 2
- SNLGQIWIFKTNLX-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2-cyanophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=CC=C1C#N SNLGQIWIFKTNLX-UHFFFAOYSA-N 0.000 claims description 2
- GBCPWXLZFQZDIS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(2-fluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=CC=C1F GBCPWXLZFQZDIS-UHFFFAOYSA-N 0.000 claims description 2
- WANYSOSCKVLFSN-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-dichlorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=C(Cl)C(Cl)=C1 WANYSOSCKVLFSN-UHFFFAOYSA-N 0.000 claims description 2
- ASKDWAVTJLHZQD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-dichlorophenyl)methyl-ethylamino]piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(O)=O)CCC1N(CC)CC1=CC=C(Cl)C(Cl)=C1 ASKDWAVTJLHZQD-UHFFFAOYSA-N 0.000 claims description 2
- OVIJNLMQPSPKKW-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-dichlorophenyl)methyl-octanoylamino]piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(O)=O)CCC1N(C(=O)CCCCCCC)CC1=CC=C(Cl)C(Cl)=C1 OVIJNLMQPSPKKW-UHFFFAOYSA-N 0.000 claims description 2
- IHTVVQYNBKRMOB-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-dichlorophenyl)methylamino]piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1NCC1=CC=C(Cl)C(Cl)=C1 IHTVVQYNBKRMOB-UHFFFAOYSA-N 0.000 claims description 2
- BBKIUXRXDFJGRB-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-difluorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=C(F)C(F)=C1 BBKIUXRXDFJGRB-UHFFFAOYSA-N 0.000 claims description 2
- ZDMDXYAYFYPJGV-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,4-difluorophenyl)methyl]piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1CC1=CC=C(F)C(F)=C1 ZDMDXYAYFYPJGV-UHFFFAOYSA-N 0.000 claims description 2
- LEMCEXKIMQLMBH-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,5-difluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC(F)=CC(F)=C1 LEMCEXKIMQLMBH-UHFFFAOYSA-N 0.000 claims description 2
- ZTLBPMDVCZQPNC-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3,5-difluorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC(F)=CC(F)=C1 ZTLBPMDVCZQPNC-UHFFFAOYSA-N 0.000 claims description 2
- GJIUYOLTRVBPAF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(3-fluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=CC(F)=C1 GJIUYOLTRVBPAF-UHFFFAOYSA-N 0.000 claims description 2
- QKDLXJGOJLYVIV-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(4-fluorophenyl)carbamoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)NC1=CC=C(F)C=C1 QKDLXJGOJLYVIV-UHFFFAOYSA-N 0.000 claims description 2
- IUNQBCIVUFJRSF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=C(F)C=C1 IUNQBCIVUFJRSF-UHFFFAOYSA-N 0.000 claims description 2
- KAFSAEVMMOAOKF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1CCN(CCCC(N)(CCCCB(O)O)C(O)=O)CC1 KAFSAEVMMOAOKF-UHFFFAOYSA-N 0.000 claims description 2
- XSYZLINBHIJHEA-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[(4-phenylphenyl)methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=C(C=2C=CC=CC=2)C=C1 XSYZLINBHIJHEA-UHFFFAOYSA-N 0.000 claims description 2
- GAZDKIOGNKBMAT-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[4-(trifluoromethyl)benzoyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 GAZDKIOGNKBMAT-UHFFFAOYSA-N 0.000 claims description 2
- DTJSPNSRLSGYEQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCC1OC1=CC=C(C(F)(F)F)C=C1 DTJSPNSRLSGYEQ-UHFFFAOYSA-N 0.000 claims description 2
- KPWYSPAFZYVFMF-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1C1=CC=C(C(F)(F)F)C=N1 KPWYSPAFZYVFMF-UHFFFAOYSA-N 0.000 claims description 2
- QUUAXWVMWKUGOR-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[4-[[3-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]propyl]hexanoic acid Chemical compound C1CN(CCCC(CCCCB(O)O)(N)C(O)=O)CCN1CC1=CC=CC(C(F)(F)F)=C1 QUUAXWVMWKUGOR-UHFFFAOYSA-N 0.000 claims description 2
- SCCWVSUTVIQDFP-NKUHCKNESA-N 2-amino-6-borono-2-[3-[[(2s)-1-methoxy-1-oxopropan-2-yl]amino]propyl]hexanoic acid Chemical compound COC(=O)[C@H](C)NCCCC(N)(C(O)=O)CCCCB(O)O SCCWVSUTVIQDFP-NKUHCKNESA-N 0.000 claims description 2
- DUNFIOOBVNXLIH-AMGKYWFPSA-N 2-amino-6-borono-2-[3-[[(2s)-1-methoxypropan-2-yl]amino]propyl]hexanoic acid Chemical compound COC[C@H](C)NCCCC(N)(C(O)=O)CCCCB(O)O DUNFIOOBVNXLIH-AMGKYWFPSA-N 0.000 claims description 2
- IAEAQRRSWUQRTO-OWYJLGKBSA-N 2-amino-6-borono-2-[3-[[(3r)-3-methoxyoxan-4-yl]amino]propyl]hexanoic acid Chemical compound CO[C@H]1COCCC1NCCCC(N)(CCCCB(O)O)C(O)=O IAEAQRRSWUQRTO-OWYJLGKBSA-N 0.000 claims description 2
- KHDGXUYUYGOSHQ-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[[4-(3,4-dichlorophenoxy)phenyl]methyl-methylamino]propyl]hexanoic acid Chemical compound C1=CC(CN(CCCC(N)(CCCCB(O)O)C(O)=O)C)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 KHDGXUYUYGOSHQ-UHFFFAOYSA-N 0.000 claims description 2
- SYKZQILTKZBFPW-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[cyclohexyl(methyl)amino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)C1CCCCC1 SYKZQILTKZBFPW-UHFFFAOYSA-N 0.000 claims description 2
- JFEOEJMIODIBJS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[cyclohexylmethyl(ethyl)amino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(CC)CC1CCCCC1 JFEOEJMIODIBJS-UHFFFAOYSA-N 0.000 claims description 2
- ZJNGIVXSLQONRA-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[cyclopentyl(methyl)amino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)C1CCCC1 ZJNGIVXSLQONRA-UHFFFAOYSA-N 0.000 claims description 2
- RXUNHNROUXVTOC-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[ethyl(naphthalen-1-ylmethyl)amino]propyl]hexanoic acid Chemical compound C1=CC=C2C(CN(CCCC(N)(CCCCB(O)O)C(O)=O)CC)=CC=CC2=C1 RXUNHNROUXVTOC-UHFFFAOYSA-N 0.000 claims description 2
- HSAKNXXHFZXDRS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[methyl(naphthalen-1-ylmethyl)amino]propyl]hexanoic acid Chemical compound C1=CC=C2C(CN(CCCC(N)(CCCCB(O)O)C(O)=O)C)=CC=CC2=C1 HSAKNXXHFZXDRS-UHFFFAOYSA-N 0.000 claims description 2
- JHESUYZIEHSKCD-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[methyl(oxan-4-yl)amino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)C1CCOCC1 JHESUYZIEHSKCD-UHFFFAOYSA-N 0.000 claims description 2
- JDXUZJZICHZIPX-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[methyl-[(4-methylnaphthalen-1-yl)methyl]amino]propyl]hexanoic acid Chemical compound C1=CC=C2C(CN(CCCC(N)(CCCCB(O)O)C(O)=O)C)=CC=C(C)C2=C1 JDXUZJZICHZIPX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- ZTCYNFKTFOXLDI-UHFFFAOYSA-N 3-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]hexanoic acid Chemical compound C1CN(C(CC(O)=O)CCC)CCN1CC1=CC=C(Cl)C(Cl)=C1 ZTCYNFKTFOXLDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- FQQJRBCEDPSMKN-UHFFFAOYSA-N 6-(2-phenylethylamino)-3-propylheptanoic acid Chemical compound CC(CCC(CC(=O)O)CCC)NCCC1=CC=CC=C1 FQQJRBCEDPSMKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- AULVYIDGJKNKSS-UHFFFAOYSA-N CCCC(CC(O)=O)CCCN(C)CCN(C)C Chemical compound CCCC(CC(O)=O)CCCN(C)CCN(C)C AULVYIDGJKNKSS-UHFFFAOYSA-N 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- WKXMUZCGWIRJAW-UHFFFAOYSA-N FC=1C=C(C=CC=1F)NC(=O)N1CCN(CC1)CCCC(C(=O)O)CCCC Chemical compound FC=1C=C(C=CC=1F)NC(=O)N1CCN(CC1)CCCC(C(=O)O)CCCC WKXMUZCGWIRJAW-UHFFFAOYSA-N 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 claims description 2
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- MPSWKTVEIKCZOH-UHFFFAOYSA-N NC(C(=O)O)(CCCCB(O)O)CCCN1C(CCC1)CC1=C(C=CC=C1)F.NC(C(=O)O)(CCCCB(O)O)CCCN1C(CCC1)C1=CC(=CC=C1)OC Chemical compound NC(C(=O)O)(CCCCB(O)O)CCCN1C(CCC1)CC1=C(C=CC=C1)F.NC(C(=O)O)(CCCCB(O)O)CCCN1C(CCC1)C1=CC(=CC=C1)OC MPSWKTVEIKCZOH-UHFFFAOYSA-N 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- KJWLSAQDUXYKPH-UHFFFAOYSA-N OB(O)CCCC(CCCC)N1CCNCC1CC1=CC=C(S(C)(=O)=O)C=C1 Chemical compound OB(O)CCCC(CCCC)N1CCNCC1CC1=CC=C(S(C)(=O)=O)C=C1 KJWLSAQDUXYKPH-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000004362 Penile Induration Diseases 0.000 claims description 2
- 208000020758 Peyronie disease Diseases 0.000 claims description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 2
- 208000005107 Premature Birth Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 2
- MKJAFOKOXVVSHQ-UHFFFAOYSA-N [5-amino-5-(2-hydroxyethoxycarbonyl)-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]octyl]boronic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1CCN(CCCC(N)(CCCCB(O)O)C(=O)OCCO)CC1 MKJAFOKOXVVSHQ-UHFFFAOYSA-N 0.000 claims description 2
- YOACIKHKOCZFMG-UHFFFAOYSA-N [5-amino-5-(2-methoxyethoxycarbonyl)-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]octyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCCOC)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 YOACIKHKOCZFMG-UHFFFAOYSA-N 0.000 claims description 2
- DYVRAPKCUGKXNH-UHFFFAOYSA-N [5-amino-5-(2-methylpropoxycarbonyl)-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]octyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCC(C)C)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 DYVRAPKCUGKXNH-UHFFFAOYSA-N 0.000 claims description 2
- VSDOVMUMCYXGDI-UHFFFAOYSA-N [5-amino-5-(3-methylbutoxycarbonyl)-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]octyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCCC(C)C)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 VSDOVMUMCYXGDI-UHFFFAOYSA-N 0.000 claims description 2
- QOXUTPJVTVHUOE-UHFFFAOYSA-N [5-amino-5-ethoxycarbonyl-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]octyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCC)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 QOXUTPJVTVHUOE-UHFFFAOYSA-N 0.000 claims description 2
- JPYTUBHCVUAQEZ-UHFFFAOYSA-N [5-amino-8-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-5-(2-morpholin-4-ylethoxycarbonyl)octyl]boronic acid Chemical compound C1COCCN1CCOC(=O)C(CCCCB(O)O)(N)CCCN(CC1)CCN1CC1=CC=C(Cl)C(Cl)=C1 JPYTUBHCVUAQEZ-UHFFFAOYSA-N 0.000 claims description 2
- RYOUSUICDBLWHC-UHFFFAOYSA-N [5-amino-8-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-5-(2-piperidin-1-ylethoxycarbonyl)octyl]boronic acid Chemical compound C1CCCCN1CCOC(=O)C(CCCCB(O)O)(N)CCCN(CC1)CCN1CC1=CC=C(Cl)C(Cl)=C1 RYOUSUICDBLWHC-UHFFFAOYSA-N 0.000 claims description 2
- SZKFSSXUAOXRLJ-UHFFFAOYSA-N [5-amino-8-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-5-(3-methylbutoxycarbonyl)octyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCCC(C)C)CCN1CC1=CC=C(Cl)C(Cl)=C1 SZKFSSXUAOXRLJ-UHFFFAOYSA-N 0.000 claims description 2
- NRWTZTLGVNXCTL-UHFFFAOYSA-N [5-amino-8-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-5-propan-2-yloxycarbonyloctyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OC(C)C)CCN1CC1=CC=C(Cl)C(Cl)=C1 NRWTZTLGVNXCTL-UHFFFAOYSA-N 0.000 claims description 2
- XDZDNXORIFRZRW-UHFFFAOYSA-N [5-amino-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]-5-pentan-3-yloxycarbonyloctyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OC(CC)CC)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 XDZDNXORIFRZRW-UHFFFAOYSA-N 0.000 claims description 2
- CRTYEPYEMLDGOM-UHFFFAOYSA-N [5-amino-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]-5-propan-2-yloxycarbonyloctyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OC(C)C)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 CRTYEPYEMLDGOM-UHFFFAOYSA-N 0.000 claims description 2
- HPYUSEOUKGODNX-UHFFFAOYSA-N [5-amino-8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]-5-propoxycarbonyloctyl]boronic acid Chemical compound C1CN(CCCC(N)(CCCCB(O)O)C(=O)OCCC)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 HPYUSEOUKGODNX-UHFFFAOYSA-N 0.000 claims description 2
- ZOYNMBBXMYWRHT-UHFFFAOYSA-N [8-[4-(3,4-dichlorophenyl)piperazin-1-yl]-5-methoxycarbonyloctyl]boronic acid Chemical compound ClC=1C=C(C=CC=1Cl)N1CCN(CC1)CCCC(CCCCB(O)O)C(=O)OC ZOYNMBBXMYWRHT-UHFFFAOYSA-N 0.000 claims description 2
- LBWNMWDUIOQNTD-UHFFFAOYSA-N [8-[4-[(4-methylsulfonylphenyl)methyl]piperazin-1-yl]-5-(2-morpholin-4-ylethoxycarbonyl)octyl]boronic acid Chemical compound CS(=O)(=O)C1=CC=C(CN2CCN(CC2)CCCC(CCCCB(O)O)C(=O)OCCN2CCOCC2)C=C1 LBWNMWDUIOQNTD-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 206010001053 acute respiratory failure Diseases 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims description 2
- 238000004555 blood preservation Methods 0.000 claims description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- ZOLFVHRUYKFNOT-UHFFFAOYSA-N diazetidine imidazolidine Chemical compound C1CNN1.C1CNCN1 ZOLFVHRUYKFNOT-UHFFFAOYSA-N 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 238000011503 in vivo imaging Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- GKFRVXOKPXCXAK-UHFFFAOYSA-N octylboronic acid Chemical compound CCCCCCCCB(O)O GKFRVXOKPXCXAK-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 210000004514 sphincter of oddi Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 150000003512 tertiary amines Chemical group 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000024883 vasodilation Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 1
- XYRRLNYDZGILAS-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[(3-chlorophenyl)methyl-methylamino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(C)CC1=CC=CC(Cl)=C1 XYRRLNYDZGILAS-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
- 0 C*1CN(*)C(CCC(CC=CCB(O)O)(C(O)=O)N)CCC1 Chemical compound C*1CN(*)C(CCC(CC=CCB(O)O)(C(O)=O)N)CCC1 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RUENUAKZNJGBHT-UHFFFAOYSA-N 2-amino-6-borono-2-[3-[ethyl(oxan-4-yl)amino]propyl]hexanoic acid Chemical compound OB(O)CCCCC(N)(C(O)=O)CCCN(CC)C1CCOCC1 RUENUAKZNJGBHT-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428894P | 2010-12-31 | 2010-12-31 | |
| US61/428,894 | 2010-12-31 | ||
| US201161450804P | 2011-03-09 | 2011-03-09 | |
| US61/450,804 | 2011-03-09 | ||
| PCT/US2011/045373 WO2012091757A1 (en) | 2010-12-31 | 2011-07-26 | Arginase inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015252736A Division JP2016117735A (ja) | 2010-12-31 | 2015-12-25 | アルギナーゼ阻害剤およびその使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014506253A JP2014506253A (ja) | 2014-03-13 |
| JP2014506253A5 true JP2014506253A5 (https=) | 2014-09-11 |
Family
ID=46380935
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547456A Pending JP2014506253A (ja) | 2010-12-31 | 2011-07-26 | アルギナーゼ阻害剤およびその使用法 |
| JP2015252736A Pending JP2016117735A (ja) | 2010-12-31 | 2015-12-25 | アルギナーゼ阻害剤およびその使用法 |
| JP2018006942A Expired - Fee Related JP6442629B2 (ja) | 2010-12-31 | 2018-01-19 | アルギナーゼ阻害剤およびその使用法 |
| JP2018220616A Expired - Fee Related JP6724115B2 (ja) | 2010-12-31 | 2018-11-26 | アルギナーゼ阻害剤およびその使用法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015252736A Pending JP2016117735A (ja) | 2010-12-31 | 2015-12-25 | アルギナーゼ阻害剤およびその使用法 |
| JP2018006942A Expired - Fee Related JP6442629B2 (ja) | 2010-12-31 | 2018-01-19 | アルギナーゼ阻害剤およびその使用法 |
| JP2018220616A Expired - Fee Related JP6724115B2 (ja) | 2010-12-31 | 2018-11-26 | アルギナーゼ阻害剤およびその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8894970B2 (https=) |
| EP (1) | EP2658580A4 (https=) |
| JP (4) | JP2014506253A (https=) |
| CN (3) | CN104857005B (https=) |
| CA (1) | CA2824599C (https=) |
| RU (2) | RU2019121905A (https=) |
| WO (1) | WO2012091757A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| HRP20160305T1 (hr) | 2010-10-26 | 2016-07-01 | Mars, Incorporated | Borati kao inhibitori arginaze |
| WO2013059437A1 (en) * | 2011-10-19 | 2013-04-25 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3134546A4 (en) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| US10143699B2 (en) | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| EP3359150A4 (en) * | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| US10562881B2 (en) | 2015-10-16 | 2020-02-18 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| SG11201802961PA (en) * | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| JP2020502259A (ja) | 2016-11-08 | 2020-01-23 | カリセラ バイオサイエンシズ，インコーポレイテッド | アルギナーゼ阻害剤併用療法 |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| KR20200008578A (ko) | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
| CN117186134A (zh) | 2018-02-17 | 2023-12-08 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| AU2019229978B2 (en) | 2018-03-05 | 2024-05-30 | Arcus Biosciences, Inc. | Arginase inhibitors |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| WO2019186497A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CN111770756B (zh) * | 2018-04-27 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| TWI828800B (zh) | 2018-11-16 | 2024-01-11 | 美商阿克思生物科學有限公司 | Arg1及/或arg2之抑制劑 |
| EP3897622B1 (en) | 2018-12-18 | 2026-01-14 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| WO2021014380A1 (en) * | 2019-07-23 | 2021-01-28 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2022272268A1 (en) * | 2021-06-23 | 2022-12-29 | Yale University | Compounds for molecular imaging of collagen turnover and methods using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477391A (en) | 1981-08-14 | 1984-10-16 | Collins James F | Amino acid isomers, their production and their medicinal use |
| US5792769A (en) * | 1995-09-29 | 1998-08-11 | 3-Dimensional Pharmaceuticals, Inc. | Guanidino protease inhibitors |
| EP0883405B1 (en) * | 1995-12-29 | 2004-02-25 | 3-Dimensional Pharmaceuticals, Inc. | Amidino protease inhibitors |
| CA2250426C (en) * | 1996-03-29 | 2006-05-02 | 3-Dimensional Pharmaceuticals, Inc. | Amidinohydrazones as protease inhibitors |
| TW499412B (en) * | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| AU9797998A (en) * | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| WO1999026926A1 (en) * | 1997-11-26 | 1999-06-03 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors |
| US6344486B1 (en) * | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| AU750561B2 (en) * | 1998-04-24 | 2002-07-25 | 3-Dimensional Pharmaceuticals, Inc. | Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors |
| NZ508669A (en) * | 1998-06-11 | 2003-06-30 | Dimensional Pharm Inc | Pyrazinone protease inhibitors |
| US6344484B1 (en) * | 1999-02-12 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Tyrosine alkoxyguanidines as integrin inhibitors |
| MXPA01011956A (es) * | 1999-05-27 | 2002-06-21 | Dimensional Pharm Inc | Oxazaheterociclos como inhibidores de proteasas. |
| US6476016B2 (en) * | 2000-07-17 | 2002-11-05 | 3-Dimensional Pharmaceuticals, Inc. | Cyclic oxyguanidine pyrazinones as protease inhibitors |
| MXPA03000963A (es) * | 2000-08-04 | 2004-04-05 | Dimensional Pharm Inc | Inhibidores de oxiguanidina ciclica proteasa. |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| AU2003218099A1 (en) | 2002-03-12 | 2003-09-29 | Lsu Medical Center | Modulation of the immune response through the manipulation of arginine levels |
| US20050176651A1 (en) * | 2002-09-09 | 2005-08-11 | Trigen Limited | Peptide boronic acids useful in making salts thereof |
| GB0405267D0 (en) * | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| EP1863431A1 (en) * | 2005-03-18 | 2007-12-12 | L'Oréal | Hair and/or eyelash care composition containing aminexil in combination with an agent for promoting the no production and uses thereof |
| CN101932599A (zh) * | 2005-11-10 | 2010-12-29 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
| LT2389352T (lt) | 2009-01-26 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Arginazės inhibitoriai ir naudojimo būdai |
| SG10201503168VA (en) | 2010-04-22 | 2015-06-29 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
-
2011
- 2011-07-26 CA CA2824599A patent/CA2824599C/en active Active
- 2011-07-26 CN CN201510164702.8A patent/CN104857005B/zh not_active Expired - Fee Related
- 2011-07-26 RU RU2019121905A patent/RU2019121905A/ru unknown
- 2011-07-26 CN CN201180068843XA patent/CN103402549A/zh active Pending
- 2011-07-26 US US13/191,160 patent/US8894970B2/en active Active
- 2011-07-26 JP JP2013547456A patent/JP2014506253A/ja active Pending
- 2011-07-26 EP EP11852428.9A patent/EP2658580A4/en not_active Withdrawn
- 2011-07-26 CN CN201910260085.XA patent/CN110123820B/zh not_active Expired - Fee Related
- 2011-07-26 WO PCT/US2011/045373 patent/WO2012091757A1/en not_active Ceased
- 2011-07-26 RU RU2013145548A patent/RU2695650C2/ru not_active Application Discontinuation
-
2015
- 2015-03-19 US US14/662,325 patent/US9447122B2/en not_active Expired - Fee Related
- 2015-12-25 JP JP2015252736A patent/JP2016117735A/ja active Pending
-
2018
- 2018-01-19 JP JP2018006942A patent/JP6442629B2/ja not_active Expired - Fee Related
- 2018-11-26 JP JP2018220616A patent/JP6724115B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506253A5 (https=) | ||
| RU2013145548A (ru) | Ингибиторы аргиназы и способы их применения | |
| CN106459067B (zh) | 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 | |
| JP2008509187A5 (https=) | ||
| ES2566205T3 (es) | Inhibidores de quinasa TYK2 | |
| US20070219239A1 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
| JP2008513515A5 (https=) | ||
| CN103781753B (zh) | 用于治疗ape1介导的疾病的醌化合物 | |
| HRP20191433T1 (hr) | Inhibitori arginaze i metode primjene | |
| JP2009512659A5 (https=) | ||
| JP2023545452A5 (https=) | ||
| US9662318B2 (en) | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof | |
| WO2003004010A1 (en) | Carbonylamino derivatives useful for obtaining immune regulation | |
| HUP0202106A2 (en) | Thienopyranecarboxamide derivatives, process for the preparation thereof, pharmaceutical compositions containing them | |
| JP2019532932A (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| US20240317717A1 (en) | Sulfonamide compounds and the use thereof in the treatment of cancer | |
| JP2008308434A (ja) | １，３−ベンゾチアジノン誘導体およびその用途 | |
| JP2006527729A5 (https=) | ||
| HK1213769B (zh) | 精氨酸酶抑制剂及其使用方法 | |
| UA91350C2 (uk) | Похідні 3-фенілпіразолу як модулятори 5-ht2a серотонінового рецептора, корисні для лікування розладів, пов'язаних з цим рецептором | |
| WO2014192847A1 (ja) | 新規なフッ素化ベンジル酸エステル化合物又はその塩 |